Comparative Pharmacology
Head-to-head clinical analysis: CEFADYL versus VELOSEF 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADYL versus VELOSEF 250.
CEFADYL vs VELOSEF '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
Bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
250 mg orally every 6 hours for adults with normal renal function.
None Documented
None Documented
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
1.2-1.5 hours in normal renal function; prolonged in renal impairment (up to 10-20 hours in ESRD)
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); remainder biliary/fecal (<10%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic